Sigma Planning’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
SL
Sigma Planning's RAPP Position: Q3 2026 in Review
Sigma Planning opened a new position in Rapport Therapeutics (RAPP) in Q3 2026: 30,000 shares worth $1.01M. The stake represents 0.03% of the portfolio and ranks #582 among its holdings.
114 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Sigma Planning held 30,000 shares of Rapport Therapeutics worth $1.01M as of Q3 2026.
- Rapport Therapeutics was a new Sigma Planning position in Q3 2026.
- Rapport Therapeutics made up 0.03% of Sigma Planning's portfolio in Q3 2026, its #582 holding.
- 114 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.